trending Market Intelligence /marketintelligence/en/news-insights/trending/rcbh77d64bqp5jpmqme9mw2 content esgSubNav
In This List

MabVax schedules reverse stock split with hopes to regain Nasdaq compliance

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


MabVax schedules reverse stock split with hopes to regain Nasdaq compliance

San Diego-based MabVax Therapeutics Holdings Inc. has scheduled its previously announced 1-to-3 reverse stock split for Feb. 16.

With the stock split, the biotech company hopes to regain compliance with Nasdaq's listing rule that requires a $1.00 minimum closing bid price for at least 10 trading days.

MabVax has until March 5 to regain compliance with the stock market.

The company previously regained compliance with Nasdaq's minimum equity requirement in November 2017.